Search

Your search keyword '"Katsev, Douglas"' showing total 18 results
Start Over Author "Katsev, Douglas"
18 results on '"Katsev, Douglas"'

2. Payment models for imaging: Procedures not covered by insurance policies: Tips to help eye care providers navigate the maze of insurance issues

Author

Katsev, Douglas and Larson, Julia Katsev

Subjects
Patients -- Care and treatment, Insurance policies, Medical care -- Quality management, Health
Abstract

One reality of ophthalmic and optometric practice is that eye care providers must navigate the medical and vision insurance payment landscapes while maintaining the highest quality of care. In some [...]

Published
2023

5. Intracameral ketorolac concentration at the beginning and end of cataract surgery following preoperative topical ketorolac administration

Author

Katsev,Douglas A, Katsev,Cailyn C, Pinnow,Jen, Lockhart,Catherine M, Katsev,Douglas A, Katsev,Cailyn C, Pinnow,Jen, and Lockhart,Catherine M

Abstract

Douglas A Katsev,1 Cailyn C Katsev,1 Jen Pinnow,2 Catherine M Lockhart3 1Santa Barbara Surgery Center, Santa Barbara, CA, 2Pinnow Consulting, Bellingham, WA, 3Omeros Corporation, seattle, WA, USA Purpose: To evaluate the intracameral concentration of ketorolac tromethamine (ketorolac) at the beginning and end of cataract surgery following preoperative topical administration.Setting: Santa Barbara Surgery Center, Santa Barbara, CA, USA.Design: This was a pre–post, interventional, single-arm study.Patients and methods: Patients undergoing cataract extraction and lens replacement (CELR) were eligible. Written informed consent was obtained from 14 patients who were prescribed topical ophthalmic ketorolac according to the surgeon’s usual practice beginning the day prior to surgery. The surgeon withdrew 100 µL of aqueous humor from the operative eye immediately prior to the initial surgical incision and again just prior to final anterior chamber reinflation and wound closure. Ketorolac concentrations in the intracameral fluid samples were measured.Results: Thirteen of 14 patients used four doses of ketorolac the day prior to surgery as directed, and one patient used three doses. On the day of surgery, all 14 patients administered one drop of topical ketorolac on awakening and one drop after arriving at the surgery center. Preoperative ketorolac concentrations for the 12 patients from whom samples were collected ranged from 4.9 to 369 ng/mL. End-of-procedure sample concentrations ranged from <1.0 (the lower limit of quantification [LLOQ]) to 6.32 ng/mL, with eight of 12 patients having ketorolac levels below the LLOQ. Conclusion: At-home compliance with topical ketorolac was good, with 92.9% of patients using it as directed. Following CELR, levels of ketorolac in the aqueous humor were low, and 66.7% of patients had undetectable levels. Keywords: cataract surgery, NSAIDs, ketorolac, topical administration, intracameral drug concentratio

Published
2017

10. Panel recommends treating ocular surface prior to any refractive procedure.

Author

Awdeh, Richard M., Donnenfeld, Eric D., Katsev, Douglas A., Kenyon, Kenneth R., McDonald, Marguerite B., Noecker, Robert J., and Perry, Henry D.

Subjects
FISH oils, AZITHROMYCIN, OPHTHALMIC drugs, CYCLOSPORINS, DRY eye syndromes, EXPERTISE, OPHTHALMIC surgery, EYELID diseases, GLAUCOMA, MEDICAL personnel, PERIOPERATIVE care, DISEASE complications, THERAPEUTICS
Abstract

The article focuses on the discussions held at the dry eye, anti-inflammatory and allergy corneal health round table to address management of ocular surface disease and informs that patients who are evaluated for Laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) have preoperative dry eye. The topics discussed included, treating aqueous deficiency dry eye, anti-inflamatory therapy in glaucoma and optimization of the ocular surface for surgery.

Published
2013

14. Making the decision to transition to laser cataract surgery.

Author

Katsev, Douglas A.

Subjects
*OPHTHALMIC surgery, *CATARACT, *COST effectiveness, *LASERS, *MEDICAL equipment, *SURGEONS, *NEW product development laws, *DECISION making in clinical medicine
Abstract

The article describes how surgeons think through the tough decision to transition to laser cataract surgery as of July 2013. It states that those who opt for transition might choose the LenSx laser platform, the only commercially available, while others may prefer to await the clinical results for the Catalys, Victus, or LensAR lasers. Others might reportedly defer selecting a lens-based laser and perform the corneal components of laser cataract surgery, such as arcuate incisions, now.

Published
2013

15. POINT / COUNTER. Do you change your intraoperative and postoperative management if you lose vitreous during cataract surgery?

Author

Katsev, Douglas A. and Kenyon, Kenneth R.

Subjects
*NONSTEROIDAL anti-inflammatory agents, *STEROID drugs, *INFLAMMATION prevention, *CATARACT, *INTRAOPERATIVE monitoring, *OPHTHALMIC surgery, *MEDICAL lasers, *POSTOPERATIVE care, *SURGICAL therapeutics, *DECISION making in clinical medicine
Abstract

The article presents answers to the question of whether intraoperative and postoperative management is changed if vitreous is lost during cataract surgery.

Published
2012

16. Increasing the Safety of Cataract Surgery in Preparation for Refractive Lensectomy.

Author

Katsev, Douglas A.

Subjects
*CATARACT surgery, *CRYSTALLINE lens diseases, *ENDOTHELIUM, *VISION disorders, *OPHTHALMOLOGY, *PHYSICIANS
Abstract

The article discusses methods for increasing the safety of cataract surgery. Ophthalmic viscosurgical device (OVD), also known as viscoelastics, increase the safety of cataract surgery by creating clarity, protecting the endothelium, easing surgical manipulation, allowing for placement stability, and helping maintain chamber pressure. A complete spectrum of OVDs are available today; the choice of viscoelastic should be guided by the best match for an individual surgeon's technique, as well as the optimum fit for a particular surgical case.

Published
2004

17. Anti-infective, NSAID dosing varies by surgeon, procedure.

Author

Charters, Lynda, Katsev, Douglas A., and Shen, Tueng

Subjects
*NONSTEROIDAL anti-inflammatory agents, *ANTI-inflammatory agents, *PREOPERATIVE care, *SURGERY, *CATARACT, *EDEMA
Abstract

The article discusses the variation in the dose of nonsteroidal anti-inflammatory agents and anti-infective drugs. How nonsteroidal anti-inflammatory agents (NSAIDs) and anti-infective drugs are used during cataract and refractive procedures varies depending with the procedure and the physician performing it. NSAIDs are mandatory for all cataract surgeries . One hour before surgery, patients receive a dose every 10 minutes. Intraoperatively, administration of an NSAID is also important because it prevents pupillary constriction. Postoperatively, the drug controls inflammation and prevents the development of cystoid macular edema.

Published
2004

18. Analysis of fifteen positional candidate genes for Schnyder crystalline corneal dystrophy.

Author

Aldave AJ, Rayner SA, Principe AH, Affeldt JA, Katsev D, and Yellore VS

Subjects
Adolescent, Adult, Child, Cholesterol metabolism, Corneal Dystrophies, Hereditary metabolism, Corneal Opacity genetics, Corneal Opacity metabolism, Corneal Stroma metabolism, Corneal Stroma pathology, DNA Mutational Analysis, Female, Genetic Markers, Granuloma, Foreign-Body genetics, Granuloma, Foreign-Body metabolism, Humans, Male, Middle Aged, Pedigree, Polymorphism, Single Nucleotide, Corneal Dystrophies, Hereditary genetics, Eye Proteins genetics
Abstract

Purpose: To identify the genetic basis of Schnyder crystalline corneal dystrophy (SCCD) through screening of positional candidate genes in affected patients., Methods: Mutation screening of fifteen genes (CORT, CLSTN1, CTNNBIP1, DFFA, ENO1, GPR157, H6PD, KIF1B, LOC440559, LZIC, MGC4399, PEX14, PGD, PIK3CD, and SSB1) that lie within the candidate gene region for SCCD was performed in members of two families affected with SCCD., Results: No presumed disease-causing mutations were identified in affected patients. Seventeen previously described single nucleotide polymorphisms (SNPs) were identified in eight of the candidate genes. Novel SNPs were identified in both affected and unaffected individuals in GPR157 (c.795C>T [Arg218Leu]; c.811C>T [Ala223Val]), MGC4399 (c.1024G>C [Leu277Leu]), and H6PD (c.754A>C [Asp151Ala])., Conclusions: No pathogenic mutations were identified in fifteen positional candidate genes in two families with SCCD. As the candidate gene region in each SCCD family previously examined with haplotype analysis has been mapped to the same chromosomal region, the absence of pathogenic mutations in these positional candidates in the families we examined reduces the number of remaining positional candidate genes by half, and the number of remaining candidate genes with a known gene function by two-thirds. We anticipate that screening of the remaining positional candidate genes will lead to the identification of the genetic basis of SCCD.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results